Standards of Medical Care in Diabetes

Diabetes Care

Volumn 27, Issue SUPPL. 1, 2004, Pages

[No Author Info available]

Author keywords

[No Author keywords available]

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; ACETYLSALICYLIC ACID; ANGIOTENSIN RECEPTOR ANTAGONIST; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; CLOPIDOGREL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; FIBRIC ACID DERIVATIVE; GLUCOSE; HEMOGLOBIN A1C; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; METFORMIN; NICOTINIC ACID; PNEUMOCOCCUS VACCINE;

ANTICOAGULANT THERAPY; BLEEDING; BLOOD GLUCOSE MONITORING; BLOOD PRESSURE REGULATION; CARDIOVASCULAR DISEASE; CHILD HEALTH CARE; CLINICAL TRIAL; COMORBIDITY; DIABETES MELLITUS; DIABETIC FOOT; DIABETIC NEPHROPATHY; DIABETIC RETINOPATHY; DIET RESTRICTION; DISEASE CLASSIFICATION; DRUG EFFICACY; DYSLIPIDEMIA; EVIDENCE BASED MEDICINE; FASTING PLASMA GLUCOSE; FLUID RETENTION; GERIATRIC CARE; GLUCOSE BLOOD LEVEL; HEALTH CARE QUALITY; HIGH RISK PATIENT; HUMAN; HYPERTENSION; IMMUNIZATION; IMPAIRED GLUCOSE TOLERANCE; ISCHEMIC HEART DISEASE; LASER COAGULATION; MEDICAL CARE; MICROALBUMINURIA; NUTRITION; ORAL GLUCOSE TOLERANCE TEST; PATIENT REFERRAL; PHYSICAL ACTIVITY; PRACTICE GUIDELINE; PREGNANCY DIABETES MELLITUS; PRENATAL CARE; PREVENTIVE MEDICINE; REVIEW; REYE SYNDROME; SCREENING; SELF MONITORING; SMOKING CESSATION;

EID: 1042302783     PISSN: 01495992     EISSN: None     Source Type: Journal    
DOI: 10.2337/diacare.27.2007.s15     Document Type: Review

References (135)

1. Bode BW (Ed.): Medical Management of Type 1 Diabetes. 4th ed. Alexandria, VA, American Diabetes Association, 2004
2. Zimmerman BR (Ed.): Medical Management of Type 2 Diabetes. 4th ed. Alexandria, VA, American Diabetes Association, 1998
3. Kilingensmith G (Ed.): Intensive Diabetes Management. 3rd ed. Alexandria, VA, American Diabetes Association, 2003
4. The Expert Committee on the Diagnosis and Classification of Diabetes Mellitus: Report of the Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Diabetes Care 20:1183-1197, 1997
5. World Health Organization: Diabetes Mellitus: Report of a WHO Study Group. Geneva, World Health Org., 1985 (Tech. Rep. Ser., no. 727)
6. The Expert Committee on the Diagnosis and Classification of Diabetes Mellitus: Follow-up report on the diagnosis of diabetes mellitus. Diabetes Care 26:3160-3167, 2003
7. Tuomilehto J, Lindstrom J, Eriksson JG, Valle TT, Hamalainen H, Ilanne-Parikka P, Keinanen-Kiukaaniemi S, Laakso M, Louheranta A, Rastas M, Salminen V, Uusitupa M: Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance. N Engl J Med 344:1343-1350, 2001
8. Pan XR, Li GW, Hu YH, Wang JX, Yang WY, An ZX, Hu ZX, Lin J, Xiao JZ, Cao HB, Liu PA, Jiang XG, Jiang YY, Wang JP, Zheng H, Zhang H, Bennett PH, Howard BV: Effects of diet and exercise in preventing NIDDM in people with impaired glucose tolerance: the DaQing IGT and Diabetes Study. Diabetes Care 20:537-544, 1997
9. The Diabetes Prevention Program Research Group: Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med 346:393-403, 2002
10. Chiasson JL, Josse RG, Gomis R, Hanefeld M, Karasik A, Laakso M: Acarbose for prevention of type 2 diabetes mellitus: the STOP-NIDDM randomized trial. Lancet 359:2072-2077, 2002
11. Sjostrom L, et al: XENDOS (Xenical in the prevention of diabetes in obese subjects): a landmark study. Poster presented at the International Congress on Obesity (ICO), San Paulo, Brazil, 2002
12. Buchanan TA, Xiang AH, Peters RK, Kjos SL, Marroquin A, Goico J, Ochoa C, Tan S, Berkowitz, Hodis HN, Azen SP: Preservation of pancreatic β-cell function and prevention of type 2 diabetes by pharmacological trewatment of insulin resistance in high-risk hispanic women. Diabetes 51:2796-2803, 2002
13. Engelgau ME, Narayan KMV, Herman WH: Screening for type 2 diabetes (Technical Review). Diabetes Care 23:1563-1580, 2000 [erratum appears in Diabetes Care 23:1868-1869, 2000]
14. Engelgau ME, Narayan KMV, Herman WH: Screening for type 2 diabetes (Technical Review). Diabetes Care 23:1563-1580, 2000 [erratum appears in Diabetes Care 23:1868-1869, 2000]
15. American Diabetes Association: Type 2 diabetes in children and adolescents (Consensus Statement). Diabetes Care 23:381-389, 2000
16. American Diabetes Association: Gestational diabetes mellitus (Position Statement). Diabetes Care 27 (Suppl. 1):S88-S90, 2004
17. The Diabetes Control and Complications Trial Research Group: The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 329: 977-986, 1993
18. The UK Prospective Diabetes Study Group: Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 352: 837-853, 1998
19. The UK Prospective Diabetes Study Group: Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet 352:854-865, 1998
20. The DCCT/EDIC Research Group: Retinopathy and nephropathy in patients with type 1 diabetes four years after a trial of intensive therapy. N Engl J Med 342:381-389, 2000
21. Lawson ML, Gerstein HC, Tsui E, Zinman B: Effect of intensive therapy on early macrovascular disease in young individuals with type 1 diabetes. Diabetes Care 22 (Suppl. 1):B35-B39, 1999
22. Stratton IM, Adler Al, Neil HA, Matthews DR, Manley SE, Cull CA, Hadden D, Turner RC, Holman RR: Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. BMJ 321:405-412, 2000
23. www.accordtrial.org
24. American Diabetes Association: Post-prandial blood glucose (Consensus Statement), Diabetes Care 24:775-778, 2001
25. Jovanovic L (Ed.): Medical Management of Pregnancy Complicated by Diabetes. 3rd ed. Alexandria, VA, American Diabetes Association, 2000
26. American Diabetes Association: Hyperglycemic crises in diabetes (Position Statement). Diabetes Care 27 (Suppl. 1): S94-S102, 2004
27. Malmberg K, for the DIGAMI Study Group: Prospective randomized study of intensive insulin treatment on long term survival after myocardial infarction in patients with diabetes. BMJ 314:512-515, 1997
28. Van den Berghe G, Wouters P, Weekers F, Verwaest C, Bruyninckx F, Schetz M, Vlasselaers D, Ferdinande P, Lauwers P, Bouillon R: Intensive insulin therapy in critically ill patients. N Engl J Med 345: 1359-1367, 2001
29. American Diabetes Association: Self-monitoring of blood glucose (Consensus Statement). Diabetes Care 17:81-86, 1994
30. American Diabetes Association: Self-monitoring of blood glucose (Consensus Statement). Diabetes Care 10:93-99, 1987
31. Sacks DB, Bruns DE, Goldstein DE, MacLaren NK, McDonald JM, Parrott M: Guidelines and recommendations for laboratory analysis in the diagnosis and management of diabetes mellitus. Diabetes Care 25:750-786, 2002
32. 1c in the Diabetes Contrrol and Complications Trial. Diabetes Care 25:275-278, 2002
33. Franz MJ, Bantle JP, Beebe CA, Brunzell JD, Chiasson JL, Garg A, Holzmeister L, Hoogwerf BJ, Mayer-Davis E, Mooradian AD, Purnell JQ, Wheeler M: Evidence-based nutrition principles and recommendations for the treatment and prevention of diabetes and related complications (Technical Review). Diabetes Care 25:148-198, 2002
34. American Diabetes Association: Nutrition principles and recommendations in diabetes (Position Statement). Diabetes Care 27 (Suppl. 1):S36-S46, 2004
35. Schneider SH, Ruderman NB: Exercise and NIDDM (Technical Review). Diabetes Care 13:785-789, 1990
36. Wasserman DH, Zinman B: Exercise in individuals with IDDM (Technical Review). Diabetes Care 17:924-937, 1994
37. Arauz-Pacheco C, Parrott MA, Raskin P: The treatment of hypertension in adult patients with diabetes mellitus (Technical Review). Diabetes Care 25:134-147, 2002
38. Haffner SM: Management of dyslipidemia in adults with diabetes (Technical Review). Diabetes Care 21:160-178, 1998
39. Colwell JA: Aspirin therapy in diabetes (Technical Review). Diabetes Care 20:1767-1771, 1997
40. Haire-Joshu D, Glasgow RE, Tibbs TL: Smoking and diabetes (Technical Review). Diabetes Care 22:1887-1898, 1999
41. American Diabetes Association: Consensus development conference on the diagnosis of coronary heart disease in people with diabetes (Consensus Statement). Diabetes Care 21:1551-1559, 1998
42. Chobanian AV, Bakris GL, Black HR, Cushman WC, Green LA, Izzo JL Jr, Jones DW, Materson BJ, Oparil S, Wright JT Jr, Roccella EJ, the National Heart, Lung, and Blood Institute Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure, the National High Blood Pressure Education Program Coordinating Committee: The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. JAMA 289:2560-2572, 2003
43. The UK Prospective Diabetes Study Group: Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. BMJ 317:703-713, 1998
44. Hansson L, Zanchetti A, Carruthers SG, Dahlof B, Elmfeldt D, Julius S, Menard J, Rahn KH, Wedel H, Westerling S: Effects of intensive blood-pressure lowering and low-dose aspirin on patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomized trial: HOT Study Group. Lancet 351:1755-1762, 1998
45. Adler AI, Stratton IM, Neil HA, Yudkin JS, Matthews DR, Cull CA, Wright AD, Turner RC, Holman RR: Association of systolic blood pressure with macrovascular and microvascular complications of type 2 diabetes (UKPDS 36): prospective observational study. BMJ 321:412-419, 2000
46. Lewington S, Clarke R, Qizilbash N, Peto R, Collins R: Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies. Lancet 360:1903-1913, 2002
47. Stamler J, Vaccaro O, Neaton JD, Wentworth D: Diabetes, other risk factors, and 12-yr cardiovascular mortality for men screened in the Multiple Risk Factor Intervention Trial. Diabetes Care 16: 434-444, 1993
48. Appel LJ, Moore TJ, Obarzanek E, Vollmer WM, Svetkey LP, Sacks FM, Bray GA, Vogt TM, Cutler JA, Windhauser MM, Lin PH, Karanja N: A clinical trial of the effects of dietary patterns on blood pressure: DASH Collaborative Research Group. N Engl J Med 336:1117-1124, 1997
49. Sacks FM, Svetkey LP, Vollmer WM, Appel LJ, Bray GA, Harsha D, Obarzanek E, Conlin PR, Miller ER 3rd, Simons-Morton DG, Karanja N, Lin PH, DASH-Sodium Collaborative Research Group: Effects on blood pressure of reduced sodium and the Dietary Approaches to Stop Hypertension (DASH) diet. N Engl J Med 344:3-10, 2001
50. Tatti P, Paahron M, Byington RP, Di Mauro P, Guarisco R, Strollo G, Strollo F: Outcome results of Fosinopril Versus Amlodipine Cardiovascular Events Randomized Trial (FACET) in patients with hypertension and NIDDM. Diabetes Care 21:597-603, 1998.
51. Estacio RO, Jeffers BW, Hiatt WR, Biggerstaff SL, Gifford N, Schrier RW: The effect of nisoldipine as compared with enalapril on cardiovascular outcomes in patients with non-insulin-dependent diabetes and hypertension. N Engl J Med 338:645-654, 1998
52. Berl T, Hunsicker LG, Lewis JB, Pfeffer MA, Porush JG, Rouleau JL, Drury PL, Esmatjes E, Hricik D, Parikh CR, Raz I, Vanhille P, Wiegmann TB, Wolfe BM, Locatelli F, Goldhaber SZ, Lewis EJ: Cardiovascular outcomes in the Irbesartan Diabetic Nephropathy Trial of patients with type 2 diabetes and overt nephropathy. Ann Intern Med 138:542-549, 2003
53. Pepine CJ, Handberg EM, Cooper-De-Hoff RM, Marks R, Kowey P, Messerli FH, Mancia G, Cangiano J, Garcia-Barreto D, Keltai M, Erdine S, Bristol HA, Kolb HR, Bakris GL, Cohen JD, Parving HH: Main outcomes from a randomized trial of a calcium antagonist (verapamil-SR) versus a noncalcium antagonist (atenolol): hypertension treatment strategy for patients with coronary artery disease: the INternational VErapamil-Transdolapril STudy (INVEST). JAMA. In press
54. The Heart Outcomes Prevention Evaluation (HOPE) Study Investigators: Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE study. Lancet 355:253-259, 2000
55. The Progress Collaborative Group: Randomized trial of a perindopril-based blood-pressure-lowering regimen among 6,105 individuals with previous stroke or transient ischaemic attack. Lancet 358:1033-1041, 2001
56. Lindholm LH, Ibsen H, Dahlof B, Devereux RB, Beevers G, de Faire U, Fyhrquist F, Julius S, Kjeldsen SE, Kristiansson K, Lederballe-Pedersen O, Nieminen MS, Omvik P, Oparil S, Wedel H, Aurup P, Edelman J, Snapinn S: Cardiovascular morbidity and mortality in patients with diabetes in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomized trial against atenolol. Lancet 359:1004-1010, 2002
57. The ALLHAT Study Group: Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA 288:2981-2997, 2002
58. The ALLHAT Collaborative Research Group: Major cardiovascular events in hypertensive patients randomized to doxazosin vs chlorthalidone: the antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT). JAMA 283:1967-1975, 2000
59. Pyorala K, Pedersen TR, Kjeksus J, Faergeman O, Olsson AG, Thorgeirsson G: Cholesterol lowering with simvastatin improves prognosis of diabetic patients with coronary heart disease: a subgroup analysis of the Scandinavian Simvastatin Study (4S). Diabetes Care 20:614-620, 1997
60. Sacks FM, Pfeffer MA, Moye LA, Rouleau JL, Rutherford JD, Cole TG, Brown L, Warnica JW, Arnold JM, Wun CC, Davis BR, Braunwald E, for the Cholesterol and Recurrent Events Trial Investigators: The effect of pravastatin on coronary events after myocardial infarction I patients with average cholesterol levels. N Engl J Med 335:1001-1009, 1996
61. The Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group: Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. N Engl J Med 339:1349-1357, 1998
62. The Heart Protection Study Collaborative Group: MRC/BHF Heart Protection Study of cholesterol-lowering with simvastatin in 5963 people with diabetes: a randomised placebo-controlled trial. Lancet 361:2005-2016, 2003
63. Frick MH, Elo O, Haapa K, Heinonen OP, Heinsalmi P, Helo P, Huttunen JK, Kaitaniemi P, Koskinen P, Manninen V: Helsinki Heart Study: primary-prevention trial with gemfibrozil in middle-aged men with dyslipidemia: safety of treatment, changes in risk factors, and incidence of coronary heart disease. N Engl J Med 317:1237-1245, 1987
64. Rubins HB, Robins SJ, Collins D, Fye CL, Anderson JW, Elam MB, Faas FH, Linares E, Schaefer EJ, Schectman G, Wilt TJ, Wittes J: Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol: Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial Study Group. N Engl J Med 341:410-418, 1999
65. The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III): Executive summary of the third report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA 285:2486-2497, 2001
66. Elam MB, Hunninghake DB, Davis KB, Garg R, Johnson C, Egan D, Kostis JB, Sheps DS, Brinton EA: Effect of niacin on lipid and lipoprotein levels and glycemic control in patients with diabetes and peripheral arterial disease. JAMA 284: 1263-1270, 2000
67. Grundy SM, Vega GL, McGovern ME, Tulloch BR, Kendall DM, Fitz-Patrick D, Ganda OP, Rosenson RS, Buse JB, Robertson DD, Sheehan JP: Efficacy, safety, and tolerability of once-daily niacin for the treatment of dyslipidemia associated with type 2 diabetes. Arch Intern Med 162:1568-1576, 2002
68. American Diabetes Association: Management of dyslipidemia in children and adolescents with diabetes (Consensus Statement). Diabetes Care 26:2194-2197, 2003
69. Kavey RW, Daniels SR, Lauer RM, Atkins DL, Hayman LL, Taubert K: American Heart Association guidelines for primary prevention of atherosclerotic cardiovascular disease beginning in childhood. Circulation 107:1562-1566, 2003
70. American Diabetes Association: Aspirin therapy in diabetes (Position Statement). Diabetes Care 27 (Suppl. 1):S72-S73, 2004
71. Hayden M, Pignone M, Phillips C: Aspirin for the primary prevention of cardiovascular events: a summary of the evidence for the U.S. Preventive Services Task Force. Ann Intern Med 136:161-171, 2002
72. US Preventive Services Task Force: Aspirin for the primary prevention of cardiovascular events: recommendation and rationale. Ann Intern Med 136:157-160, 2002
73. Bhatt DL, Marso SP, Hirsch AT, Ringleb PA, Hacke W, Topol EJ: Amplified benefit of clopidogrel versus aspirin in patientrs with diabetes mellitus. Am J Cardiol 90:625-628, 2002
74. American Diabetes Association: Smoking and diabetes (Position Statement). Diabetes Care 27 (Suppl. 1):S74-S75, 2004
75. US Preventive Services Task Force: Counseling to prevent tobacco use. In Guide to Clinical Preventive Services. 2nd ed. Baltimore, MD, Williams & Wilkins, 1996, p. 597-609
76. Fiore M, Bailey W, Cohen S: Smoking Cessation: Clinical Practice Guideline Number 18. Rockville, MD, U.S. Department of Health and Human Services, Public Health Service, Agency for Health Care Policy and Research, 1996
77. Garg J, Bakris GL: Microalbuminuria: marker of vascular dysfunction, risk factor for cardiovascular disease. J Vasc Med 7:35-43, 2002
78. Gall MA, Hougaard P, Borch-Johnsen K, Parving HH: Risk factors for development of incipient and overt diabetic nephropathy in patients with non-insulin dependent diabetes mellitus: prospective, observational study. BMJ 314:783-788, 1997
79. Ravid M, Lang R, Rachmani R, Lishner M: Long-term renoprotective effect of angiotensin-converting enzyme inhibition in non-insulin-dependent diabetes mellitus: a 7-year follow-up study. Arch Intern Med 156:286-289, 1996
80. Reichard P, Nilsson B-Y, Rosenqvist U: The effect of long-term intensified insulin treatment on the development of microvascular complications of diabetes mellitus. N Engl J Med 329:304-309, 1993
81. The DCCT Research Group: Effect of intensive therapy on the development and progression of diabetic nephropathy in the Diabetes Control and Complications Trial (DCCT). Kidney Int 47:1703-1720, 1995
82. Lewis EJ, Hunsicker LG, Bain RP, Rohde RD, for the Collaborative Study Group: The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. N Engl J Med 329:1456-1462, 1993
83. Laffel LMB, McGill JB, Gans DJ, the North American Microalbuminuria Study Group (NAMSG): The beneficial effect of angiotensin-converting enzyme inhibition with captopril on diabetic nephropathy in normotensive IDDM patients with microalbuminuria. Am J Med 99:497-504, 1995
84. Bakris GL, Williams M, Dworkin L, Elliott WJ, Epstein M, Toto R, Tuttle K, Douglas J, Hsueh W, Sowers J: Preserving renal function in adults with hypertension and diabetes: a consensus approach: National Kidney Foundation Hypertension and Diabetes Executive Committees Working Group. Am J Kidney Dis 36:646-661, 2000
85. Lewis EJ, Hunsicker LG, Clarke WR, Berl T, Pohl MA, Lewis JB, Ritz E, Atkins RC, Rohde R, Raz I: Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med 345:851-860, 2001
86. Brenner BM, Cooper ME, de Zeeuw D, Keane WF, Mitch WE, Parving HH, Remuzzi G, Snapinn SM, Zhang Z, Shahinfar S: Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 345:861-869, 2001
87. Parving HH, Lehnert H, Brochner-Mortensen J, Gomis R, Andersen S, Arner P: The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes. N Engl J Med 345:870-878, 2001
88. Bakris GL, Siomos M, Richardson Janssen I, Bolton WK, Hebert L, Agarwal R, Catanzaro D: ACE inhibition or angiotensin receptor blockade: impact on potassium in renal failure: VAL-K Study Group. Kidney Int 58:2084-2092, 2000
89. Black HR, Elliott WJ, Grandits G, Grambsch P, Lucente T, White WB, Neaton JD, Grimm Jr RH, Hansson L, Lacourciere Y, Muller J, Sleight P, Weber MA, Williams G, Wittes J, Zanchetti A, Anders RJ: Principal results of the Controlled Onset Verapamil Investigation Of Cardiovascular End Points (CONVINCE) trial. JAMA 289:2073-2082, 2003
90. Pepine CJ, Handberg EM, Cooper-De-Hoff RM, Marks R, Kowey P, Messerli FH, G Mancia, Cangiano J, Garcia-Barreto D, Keltai M, Erdine S, Bristol HA, Kolb HR, Bakris GL, Cohen JD, Parving HH, Erdine: Main outcomes from a randomized trial of a calcium antagonist (Verapamil-SR) versus a noncalcium antagonist (Atenolol) hypertension treatment strategy for patients with coronary artery disease: the INternational VErapamil-Trandolapril STudy (INVEST). JAMA. In Press
91. Anderson S, Tarnow L, Rossing P, Hansen BV, Parving HH: Renoprotective effects of angiotensin II receptor blockade in type 1 diabetic patients with diabetic nephropathy. Kidney Int 57:601-606, 2000
92. Eknoyan G, Hostetter T, Bakris GL, Hebert L, Levey AS, Parving HH, Steffes MW, Toto R: Proteinuria and other markers of chronic kidney disease: A position statement of the national kidney foundation (NKF) and the national institute of diabetes and digestive and kidney diseases (NIDDK). Am J Kidney Dis 42: 617-622, 2003
93. K/DOQI Clinical Practice Guidelines for Chronic Kidney Disease: Evaluation, Classification, and Stratification. Kidney Disease Outcome Quality Initiative. Am J Kidney Dis 39 (Suppl. 2):S1-S246, 2002
94. Levey S, Bosch J, Lewis B, Greene T, Rogers N, Roth D: A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation: Modification of Diet in Renal Disease Study Group. Ann Intern Med 130:461-470, 1999
95. Levinsky N: Specialist of evaluation in chronic kidney disease: too little, too late. Ann Intern Med 137:542-543, 2002
96. American Diabetes Association: Nephropathy in Diabetes (Position Statement). Diabetes Care 27 (Suppl. 1):S79-S83, 2004
97. Aiello LP, Gardner TW, King GL, Blankenship G, Cavallerano JD, Ferris FL, Klein R: Diabetic retinopathy (Technical Review). Diabetes Care 21:143-156, 1998
98. The Diabetes Control and Complications Trial Research Group: Effect of pregnancy on microvascular complications in the Diabetes Control and Complications Trial. Diabetes Care 23:1084-1091, 2000
99. Vijan S, Hofer TP, Hayward RA: Cost-utility analysis of screening intervals for diabetic retinopathy in patients with type 2 diabetes mellitus. JAMA 283: 889-896, 2000
100. Klein R: Screening interval for retinopathy in type 2 diabetes. Lancet 361:190-191, 2003
101. Younis N, Broadbent DM, Vora JP, Harding SP: Incidence of sight-threatening retinopathy in patients with type 2 diabetes in the Liverpool Diabetic Eye Study: a cohort study. Lancet 361:195-200, 2003
102. The Diabetic Retinopathy Study Research Group: Preliminary report on effects of photocoagulation therapy. Am J Ophthalmol 81:383-396, 1976
103. The Diabetic Retinopathy Study Research Group: Four risk factors for severe visual loss in diabetic retinopathy: the third report of the Diabetic Retinopathy Study. Arch Opthalmol 97:654-655, 1979
104. The Diabetic Retinopathy Study Research Group: Design, methods, and baseline results: DRS report no. 6. Invest Ophthalmol Vis Sci 21:149-209, 1981
105. The Diabetic Retinopathy Study Research Group: Photocoagulation treatment of proliferative diabetic retinopathy: clinical application of Diabetic Retinopathy Study (DRS) findings: DRS report number 8. Opthalmology 88:583-600, 1981
106. The Diabetic Retinopathy Study Research Group: Indications for photocoagulation treatment of diabetic retinopathy: DRS report no. 14. Int Opthalmol Clin 27:239-253, 1987
107. The Early Treatment Diabetic Retinopathy Study Research Group: Photocoagulation for diabetic macular edema: ETDRS report no. 1. Arch Opthalmol 103:1796-1806, 1985
108. The Early Treatment Diabetic Retinopathy Study Research Group: Treatment techniques and clinical guidelines for photocoagulation of diabetic macular edema: ETDRS report number 2. Opthalmology 94:761-774, 1987
109. The Early Treatment Diabetic, Retinopathy Study Research Group: Techniques for scatter and local photocoagulation treatment of diabetic retinopathy: ETDRS report no. 3. Int Ophthalmol Clin 27: 254-264, 1987
110. The Early Treatment Diabetic Retinopathy Study Research Group: Photocoagulation for diabetic macular edema: ETDRS report no. 4. Int Opthalmol Clin 27:265-272, 1987
111. The Early Treatment Diabetic Retinopathy: Study design and baseline patient characteristics: ETDRS report number 7. Opthalmology 98:741-756, 1991
112. The Early Treatment Diabetic Retinopathy Study Research Group: Effects of aspirin treatment on diabetic retinopathy: ETDRS report number 8. Opthalmology 98 (Suppl.):757-765, 1991
113. The Early Treatment Diabetic Retinopathy Study Research Group: Early photocoagulation for diabetic retinopathy: ETDRS report no. 9. Opthalmology 98: 766-785, 1991
114. American Diabetes Association: Retinopathy in diabetes (Position Statement). Diabetes Care 27 (Suppl. 1):S84-S87, 2004
115. Ciulla TA, Amador AG, Zinman B: Diabetic retinopathy and diabetic macular edema: pathophysiology, screening, and novel therapies. Diabetes Care 26:2653-2664, 2003
116. American Diabetes Association: Peripheral arterial disease in people with diabetes (Consensus Statement). Diabetes Care 26:3333-3342, 2003
117. Mayfield JA, Reiber GE, Sanders LJ, Janisse D, Pogach LM: Preventive foot care in people with diabetes (Technical Review). Diabetes Care 21:2161-2177, 1998
118. American Diabetes Association: Preventive foot care in diabetes (Position Statement). Diabetes Care 27 (Suppl. 1):S63-S64, 2004
119. American Diabetes Association: Consensus Development Conference on Diabetic Foot Wound Care (Consensus Statement). Diabetes Care 22:1354-1360, 1999
120. Kitzmiller JL, Gavin LA, Gin GD, Jovanovic-Peterson L, Main EK, Zigrang WD: Preconception care of diabetes: glycemic control prevents excess congenital malformations. JAMA 265:731-736, 1991
121. Goldman JA, Dicker D, Feldberg D, Yeshaya A, Samuel N, Karp M: Pregnancy outcome in patients with insulin-dependent diabetes mellitus with preconception diabetic control: a comparative study. Am J Obstet Gynecol 155:293-297, 1986
122. Rosenn B, Miodovnik M, Combs CA, Khoury J, Siddiqi TA: Pre-conception management of insulin-dependent diabetes: improvement of pregnancy outcome. Obstet Gynecol 77:846-849, 1991
123. Tchobroutsky C, Vray MM, Altman JJ: Risk/benefit ratio of changing late obstetrical strategies in the management of insulin-dependent diabetic pregnancies. Diabete Metab 17:287-294, 1991
124. Willhoite MB, Bennert HW Jr, Palomaki GE, Zaremba MM, Herman WH, Williams JR, Spear NH: The impact of preconception counseling on pregnancy outcomes. Diabetes Care 16:450-455, 1993
125. Kitzmiller JL, Buchanan TA, Kjos S, Combs CA, Ratner R: Pre-conception care of diabetes, congenital malformations, and spontaneous abortions (Technical Review). Diabetes Care 19:514-541, 1996
126. American Diabetes Association: Pre-conception care of women with diabetes (Position Statement). Diabetes Care 27 (Suppl. 1):S76-S78, 2004
127. Colquhoun AJ, Nicholson KG, Botha NT: Effectiveness of influenza vaccine in reducing hospital admissions in people with diabetes. Epidemiol Infect 119:335-341, 1997
128. Centers for Disease Control and Pre-vention: Prevention and control of influenza: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR 51 (no. RR-3), 2002
129. Centers for Disease Control and Prevention: Prevention and control of pneumococcal disease: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR 46 (no. RR-08), 1997
130. Smith SA, Poland GA: The use of influenza and pneumococcal vaccines in people with diabetes (Technical Review). Diabetes Care 23:95-108, 2000
131. American Diabetes Association: Influenza and pneumococcal immunization in diabetes (Position Statement). Diabetes Care 27 (Suppl. 1):S111-S113, 2004
132. The California Healthcare Foundation/American Geriatric Society on Improving Care for Elders with Diabetes: Guidelines for improving the care of the older person with diabetes mellitus. Am J Geriatric Soc 51:S265-S280, 2003
133. Fagot-Campagna A, Pettitt DJ, Engelgau MM, Burrows NR, Geiss LS, Valdez R, Beckles GL, Saaddine J, Gregg EW, Williamson DF, Narayan KM: DM2 among North American children and adolescents: an epidemiologic review and a public health perspective. J Pediatr 136: 664-672, 2000
134. ahagan S, Silverstein J, the American Academy of Pediatrics Committee on Native American Child Health, the American Academy of Pediatrics Section on Endocrinology: Prevention and treatment of type 2 diabetes mellitus in children, with special emphasis on American Indian and Alaska Native children. Pediatrics 112:e328, 2003
135. American Diabetes Association: Diabetes care in the school and day care setting (Position Statement). Diabetes Care 27 (Suppl. 1):S122-S128, 2004